James Shortridge, DO
Hematology & Oncology · Salt Lake City, UTNPI 1205148061
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.3%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Daiichi Sankyo Inc. at 37.3% of the total. 2025 is the largest year on record at $6,102, more than ten times the $190 reported in 2019.
Across 242 payments — averaging $35.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$3K
- Geron Corporation$826
- Cornerstone Specialty Network LLC$650
- AstraZeneca$527
- Novartis$460
- Pfizer$402
- plus $3K from 30 others
What the payments were for
- Consulting fees$3,24338%
- Speaking & faculty fees$6508%
- Food & beverage$4,61253%
- Education$1432%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 43 | $3,224 |
| Geron Corporation | 3 | $826 |
| Cornerstone Specialty Network LLC | 1 | $650 |
| AstraZeneca | 23 | $527 |
| Novartis | 27 | $460 |
| Pfizer | 27 | $402 |
| Johnson & Johnson | 10 | $332 |
| E.r. Squibb & Sons, L.L.C. | 16 | $289 |
| Incyte Corporation | 9 | $206 |
| Merck | 9 | $183 |
| Lilly USA, LLC | 5 | $148 |
| EMD Serono, Inc. | 7 | $142 |
| Array Biopharma Inc | 10 | $136 |
| GSK | 6 | $125 |
| Eisai Inc. | 6 | $112 |
| Genmab U.S., Inc. | 5 | $105 |
| AbbVie | 5 | $104 |
| Beone Medicines USA, Inc. | 3 | $83 |
| Sanofi | 2 | $76 |
| Bayer | 3 | $56 |
| Astellas Pharma US Inc | 2 | $45 |
| Pharmaessentia USA Corporation | 2 | $43 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| Bristol Myers Squibb | 2 | $39 |
| Gilead | 2 | $37 |
| Tersera Therapeutics LLC | 1 | $37 |
| Puma Biotechnology, Inc. | 2 | $33 |
| Beigene USA, Inc. | 1 | $29 |
| Genentech USA, Inc. | 1 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $25 |
| Recordati_rare_diseases_inc. | 1 | $21 |
| Deciphera Pharmaceuticals Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Stemline Therapeutics Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| Seagen Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,648 in reported general payments places this provider in the 60th percentile of 77 hematology & oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 57 | $1,044,165 |
| CalquenceAcalabrutinib Maleate | 64 | $920,664 |
| IbrancePalbociclib | 53 | $770,048 |
| Lenalidomide | 40 | $653,440 |
| ImbruvicaIbrutinib | 53 | $600,914 |
| PomalystPomalidomide | 17 | $391,921 |
| BrukinsaZanubrutinib | 23 | $343,812 |
| KisqaliRibociclib Succinate | 23 | $337,577 |
| BesremiRopeginterferon Alfa-2b-Njft | 19 | $291,808 |
| AlecensaAlectinib Hcl | 13 | $248,495 |
| PromactaEltrombopag Olamine | 13 | $246,549 |
| TagrissoOsimertinib Mesylate | 14 | $210,146 |
| XtandiEnzalutamide | 13 | $175,143 |
| GilotrifAfatinib Dimaleate | 13 | $151,267 |
| ErivedgeVismodegib | 11 | $138,230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso | $527 | $1,130,80978 claims |
| Bristol Myers SquibbRevlimid | $39 | $1,044,16557 claims |
| PfizerIbrance, Eliquis | $402 | $800,97891 claims |
| NovartisKisqali, Promacta | $460 | $584,12536 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $289 | $391,92117 claims |
| Genentech USA, Inc.Alecensa, Erivedge | $25 | $386,72624 claims |
| Beigene USA, Inc.Brukinsa | $29 | $343,81223 claims |
| Pharmaessentia USA CorporationBesremi | $43 | $291,80819 claims |
| Astellas Pharma US IncXtandi | $45 | $175,14313 claims |
| Boehringer IngelheimGilotrif | $18 | $151,26713 claims |
| Johnson & JohnsonXarelto | $332 | $22,04721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 77 hematology & oncology providers in Utah.
Other hematology & oncology in Salt Lake City
- Douglas SborovSalt Lake City$473K
- Daniel CourielSalt Lake City$229K
- Shiven PatelSalt Lake City$223K
- Neeraj AgarwalSalt Lake City$159K
- Benjamin MaughanSalt Lake City$142K
- Schickwann TsaiSalt Lake City$137K
- Heloisa SoaresSalt Lake City$111K
- Daanish HodaSalt Lake City$80K
- Tsewang TashiSalt Lake City$69K
- Finn PetersenSalt Lake City$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.